We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Study Sheds Light on Preventing PXR-Associated Drug Resistance

A scientist pipetting into a test tube.
Credit: iStock.
Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: 2 minutes

Deaths from cancer or infections can occur when available treatments are ineffective. Once turned on, pregnane X receptor (PXR) activates the expression of genes encoding enzymes that metabolize external chemicals, including drugs. This causes a significant drop in the effectiveness of chemotherapy, antivirals and other pharmaceuticals. Blocking the PXR activity is notoriously difficult, as many drugs that bind the protein, whether intentionally or unintentionally, activate it. Scientists at St. Jude Children’s Research Hospital have leveraged chemical and structural studies in the design of PXR inhibitors to better understand this process. The findings, published in Nature Communications, provide new insights into the relationship between compounds that activate PXR and ones that block its activity, with implications for designing more effective therapeutics.

Removing toxic compounds from our bodies is a vital process to maintain overall health and wellbeing. To accomplish this, the human body has a toxin removal system. A family of proteins called cytochrome P450 plays a significant role in this process; however, these proteins do not discriminate between toxins and well-intentioned therapeutics. Higher drug doses are often needed to overcome the work these proteins do to eliminate drugs and toxins alike from the body. Cytochrome P450 protein levels are elevated when a drug binds to and activates their respective regulators, such as nuclear receptors, which in turn activates cytochrome P450 genes’ expression. In particular, PXR regulates the expression of a central player in drug metabolism, CYP3A4.

Want more breaking news?

Subscribe to Technology Networks’ daily newsletter, delivering breaking science news straight to your inbox every day.

Subscribe for FREE

PXR activates drug-removing cytochrome P450 hitmen

“PXR is a transcription factor that regulates the gene expression of CYP3A4, and when a drug binds to and activates PXR, it upregulates CYP3A4,” said corresponding author Taosheng Chen, PhD, St. Jude Department of Chemical Biology & Therapeutics. “CYP3A4 metabolizes more than half of drugs on the market, so it’s clear how important it is.”

CYP3A4 inhibitors, such as ritonavir, have shown benefit when used in combination with the anti-SARS-CoV-2 drug Paxlovid by stopping its active ingredient, nirmatrelvir, from being metabolized by CYP3A4 too quickly. Directly inhibiting PXR activity represents an alternative solution to control drug metabolism by CYP3A4. If drug-metabolizing proteins like CYP3A4 are the hired goons, then PXR represents the mob boss.

The researchers’ challenge was overcoming generations of PXR evolution, which has turned the protein into a juggernaut of ligand promiscuity. “Lots of compounds can bind to PXR,” explained Chen. “There are even very small compounds that by themselves, are inactive. But if you combine a few of them, they can bind to different areas of PXR and together activate it.” The flexibility that allows it to bind thousands of different compounds also means inhibiting its function requires a deft touch.

Previous work from the Chen lab on PXR inhibitor discovery identified the inhibitor SPA70 as a potent candidate. But as a testament to PXR’s unique capabilities, very minor changes to SPA70 flipped it into an activator rather than an inhibitor. In this study, Chen and his team leveraged chemical and structural studies to understand the molecular basis behind the subtle differences between activator and inhibitor binding. 

Reference: Garcia-Maldonado E, Huber AD, Chai SC, et al. Chemical manipulation of an activation/inhibition switch in the nuclear receptor PXR. Nat Comm. 2024;15(1):4054. doi: 10.1038/s41467-024-48472-1

This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source. Our press release publishing policy can be accessed here.